Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 382 participants.

Also called NCT07302854

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 382 participants (planned count) (from the registry)
Sponsor
  • Xiang Luo Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07302854
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07302854. Randomized; single masking; primary purpose treatment. Start 2025-12-30 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion
Acronym
MeVO-TNK Ⅱ
Condition
Acute Ischemic Stroke
Condition
Medium Vessel Occlusion
Intervention (Procedure)
Intra-arterial Thrombolysis
Intervention (Drug)
Standard medical treatment
Lead sponsor
Xiang Luo (class: other)

Record details

Record id
cardio:ct-nct07302854
Content hash
b6590cac09782e1980f56bc818b51753928570a238e2bb6b311cfe845e540bd3